The Irvine, Calif.-based medical devicemaker expects more than half of its revenue will come from sales of its transcatheter aortic valve replacement business, which it predicts will see a 15 percent sales growth in 2020.
The company told MedTech Dive its growth estimate is based on factors including an aging population, health systems prioritizing structural heart care and increased awareness of transcatheter technologies.
The company has a history of underestimating its market goals, analysts at Jeffries, a New York City-based investment banking firm, told MedTechDive.
Read the full article here.
More articles on supply chain:
Viant to shut down sterilization operations at Michigan facility
Hahnemann hospital auctioning off medical equipment, supplies
UPS names president of healthcare unit
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
